FDA Issues More Warning Letters, Drops Follow-Up Letters In Favor Of Action
This article was originally published in The Tan Sheet
Executive Summary
FDA will warn firms only once - if at all - before taking stronger enforcement actions to stop systematic quality and safety problems, said Howard Sklamberg, director of the Office of Enforcement at the Office of Regulatory Affairs
You may also be interested in...
Better Intra-Agency Reviews Could Speed FDA Seizure, Injunction Decisions
FDA is working to expedite its decision-making process for seizures and injunctions, which could translate into quicker enforcement actions for violative products.
Better Intra-Agency Reviews Could Speed FDA Seizure, Injunction Decisions
FDA is working to expedite its decision-making process for seizures and injunctions, which could translate into quicker enforcement actions for violative products.
Better Intra-Agency Reviews Could Speed FDA Seizure, Injunction Decisions
FDA is working to expedite its decision-making process for seizures and injunctions, which could translate into quicker enforcement actions for violative products.